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psychiatric symptoms (Brief Symptom Inventory), psychoso-
cial functioning (Outcome Questionnaire-45), and quality of 
life (EQ-5D), using multilevel statistical modelling. As the 
study was non-randomised, the propensity score method 
was used to control for initial differences.  Results: Patients 
in all 3 settings improved significantly in terms of psychiatric 
symptoms, social and interpersonal functioning, and quality 
of life 18 months after baseline. The inpatient group showed 
the largest improvements. The comparison of outpatient 
and inpatient treatment regarding psychiatric symptoms 
showed a marginally significant result (p = 0.057) in favour of 
inpatient treatment.  Conclusions: Patients with cluster B 
personality disorders improved in all investigated treatment 
settings, with a trend towards larger improvements of psy-
chiatric symptoms in the inpatient setting compared to the 
outpatient setting. Specialised inpatient treatment should 
be considered as a valuable treatment option for cluster B 
personality disorders, both in research and in clinical prac-
tice.  Copyright © 2010 S. Karger AG, Basel
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 Abstract
 Background: For patients with cluster B personality disor-
ders there is no consensus regarding the optimal treatment 
setting. The aim of this study was to compare the effective-
ness of different psychotherapeutic settings for patients 
with cluster B personality disorders, i.e. outpatient, day hos-
pital, and inpatient treatment.  Methods: The study was con-
ducted between March 2003 and June 2008 in 6 mental 
health care centres in the Netherlands, with a sample of 207 
patients with a DSM-IV-TR axis II cluster B diagnosis. Patients 
were assigned to 3 different settings of psychotherapeutic 
treatment and effectiveness was assessed at 18 months after 
baseline. An intention-to-treat analysis was conducted for 
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 Introduction
 Cluster B personality disorders (PD) affect a consider-
able percentage of the general population (3.1–4.5%)  [1, 2] 
and are highly prevalent in psychiatric patients (13.0%) 
 [3] . Borderline, histrionic, narcissistic, and antisocial PD 
are not only associated with individual suffering  [4–7] , 
but also with early institutional care and criminality  [8] . 
They place a heavy burden on both individuals and soci-
ety as a whole  [9–13] . To date, a number of specific treat-
ment protocols tailored to this patient group have been 
developed. This is especially the case for borderline
PD  [14, 15] . Examples are dialectical behaviour therapy 
 [16] , mentalization-based treatment  [17] , schema-focused 
therapy  [18] , and transference-focused therapy  [19] . As a 
consequence, methodologically sound research on psy-
chotherapeutic treatments for cluster B PD has increased 
during the last 10 years. However, no study has directly 
compared outpatient, day hospital, and inpatient treat-
ment within one patient sample. The available published 
studies have focused either on the development of spe-
cific treatment manuals and their evaluation  [20–29] or 
on the comparison of different theoretical schools within 
outpatient settings  [30–32] . Another focus of psychother-
apy outcome research was the effectiveness of specific 
treatment ingredients, such as transference interpreta-
tions  [33, 34] or crisis support outside office hours  [35] . 
So until now, hardly any study has addressed possible dif-
ferences in treatment effectiveness between different set-
tings and across theoretical schools. Exceptions are the 
studies by Chiesa et al.  [36–38] comparing inpatient 
treatment and step-down/outpatient treatment and the 
study by Arnevik et al.  [39] comparing day hospital treat-
ment and outpatient treatment. 
 Comparing different treatment settings is relevant as 
it can be anticipated that the type of setting will affect 
costs for both patients and society, as well as patients’ 
time. One of the reasons this comparison (e.g. outpatient 
versus day hospital versus inpatient treatment) has not 
been made previously is probably the difficulty of ran-
domly assigning patients to different treatment settings 
in clinical samples due to practical or ethical constraints 
 [40] . Furthermore, even if researchers were successful in 
setting up and starting a randomised treatment setting 
study, external validity would be doubtful because a high 
number of patients would probably refuse to participate. 
In non-randomised studies, however, researchers often 
cannot draw valid conclusions due to the strong influ-
ence of selection bias. Accordingly, there is a need to de-
sign and conduct non-randomised effectiveness studies 
while minimising the influence of selection bias. This 
kind of study is increasingly being found in the literature 
 [41–44] . In the present study, this has been undertaken 
for the first time in a population of cluster B PD patients 
using the propensity score method to minimise the influ-
ence of selection bias. 
 The purpose of our study was to compare the effective-
ness of different treatment settings (outpatient, day hos-
pital, inpatient) in psychotherapy for cluster B PD 18 
months after baseline. The primary outcome measure in 
this study was psychiatric symptomatology. Additionally, 
effects on interpersonal and social functioning as well as 
on quality of life were evaluated. 
 Method
 Participants
 Participants (n = 207) were recruited from consecutive ad-
missions to 6 mental health care centres in the Netherlands (Cen-
tre of Psychotherapy De Viersprong, Halsteren; Altrecht, Utrecht; 
Zaans Medical Centre, Zaandam; Centre of Psychotherapy De 
Gelderse Roos, Lunteren; GGZWNB, Bergen op Zoom and Roo-
sendaal; Arkin, Amsterdam). These institutions offer outpatient, 
day hospital, and/or inpatient psychotherapy for patients with PD. 
From March 2003 to March 2006, 1,379 patients completed the 
intake and screening procedure and were selected for treatment 
( fig. 1 ). The intake and screening data were collected for all appli-
cants, irrespective of study participation later on. The data ob-
tained from this initial assessment served as baseline data for our 
study. As it was part of the standard screening procedure, in-
formed consent for the baseline data collection was not manda-
tory under Dutch law. 
 Of these 1,379 patients, 146 (10.6%) were excluded from the 
study for not meeting one of the following inclusion criteria: age 
between 18 and 70 years (n = 13), significant personality pathol-
ogy (n = 34), and referral for psychotherapeutic treatment aimed 
at personality problems (n = 99). Nine patients (0.7%) met one of 
the following exclusion criteria: insufficient command of the 
Dutch language (n = 6), organic cerebral impairment (n = 1), men-
tal retardation (n = 1), and schizophrenia (n = 1). This left 1,224 
eligible participants, of whom 31 (2.5%) could not participate due 
to logistic reasons (e.g. no appointment could be made to provide 
informed consent). A total of 133 patients (10.9%) had to be ex-
cluded due to missing or unreliable baseline data during the in-
take and screening procedure. For the majority of these 133 pa-
tients (n = 106), no standardised axis II diagnosis was obtained. 
This was mostly due to a practical problem, i.e. a shortage of in-
terviewers at the start of the study (n = 101). Because of this logis-
tic reason, it can be assumed that these data were ‘missing com-
pletely at random’ and therefore they do not threaten internal va-
lidity (as they were unrelated to specific patient characteristics). 
Five patients had an unreliable axis II diagnosis as determined by 
the interviewer, for example because the patient was too anxious 
or too depressed to obtain a reliable diagnosis with a semi-struc-
tured interview. A few patients did not return their assessment 
booklet during the intake procedure (n = 27). Thirty-eight pa-
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tients (3.1%) received less than 2 treatment sessions of outpatient 
therapy or less than 2 days of inpatient or day hospital therapy. 
For example, some of the patients left treatment after 1 session, 
and some did not even show up for the first session. They were 
therefore excluded beforehand from the study sample in which we 
only included patients with a ‘minimal effective dose’ of treat-
ment. One hundred patients (8.2%) refused to participate. The 
remaining 922 patients were informed about the study and its 
procedure, provided written informed consent, and entered the 
study. Of those, 245 patients (26.6%) had 1 or more cluster B PD. 
 In the absence of explicit guidelines for treatment assignment 
in PD  [45] , the selection procedure was based on the expert opin-
ion of clinicians who used their clinical experience combined 
with patient data from standardised instruments. To clarify the 
criteria used for the assignment process, our research group had 
recently conducted a study with intake clinicians from the par-
ticipating treatment centres. We found evidence of substantial 
consensus among clinicians concerning the criteria used for 
treatment decision making  [46] . 
 Patients were assigned to 1 of 3 setting groups: 59 to outpatient, 
99 to day hospital, and 87 to inpatient psychotherapy. Follow-up 
data were not available for 38 patients (15.5%, patients who did not 
respond to any follow-up assessment or patients where follow-up 
measurements were as yet not available). There was no difference 
in psychiatric symptoms at baseline between patients with follow-
up data and those without (this holds true for both the compari-
son in the total sample and the comparison within the 3 treatment 
groups). The final sample consisted of 207 patients who were in-
cluded in the intention-to-treat analyses. 
Assessed for eligibility
(n = 1,379)
Enrolled
(n = 960)
Outpatient
treatment
(n = 59)
Day hospital
treatment
(n = 99)
Inpatient
treatment
(n = 87)
Refused to participate
(n = 100)
Excluded due to other reasons
(n = 164)
(logistic reasons n = 31,
missing/unreliable data n = 133)
Did not meet inclusion criteria
(n = 146)
Met exclusion criteria
(n = 9)
No DSM-IV cluster B PD
diagnosis
(n = 677)
Lost to follow-up
(n = 13)
Lost to follow-up
(n = 18)
Lost to follow-up
(n = 7)
Analyzed
(n = 46)
Analyzed
(n = 81)
Analyzed
(n = 80)
Dropped out prematurely1
(n = 38)
Allocated
(n = 245)
 Fig. 1. Patient flow.  1  These patients did not 
receive a ‘minimal effective dose’ of treat-
ment, defined as two sessions for outpa-
tients and two treatment days for day hos-
pital patients and inpatients, and were 
therefore not included in the initial study 
sample. 
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 Treatment
 The 6 mental health care centres offer a variety of psychother-
apeutic treatments tailored to a PD patient population. Their 
treatments differ according to several features. As this study fo-
cused on different treatment settings, the following 3 treatment 
groups were compared: 
 (1) Patients in the outpatient treatment group (n = 46, 22.2% 
of the study sample). These patients came for individual (89.2%) 
or group (10.9%) psychotherapy sessions for up to 2 sessions 
(mean 0.7 sessions/week, SD 0.4, median 0.5) per week (mean 
treatment duration 14.5 months, SD 6.6, median 12.0).
 (2) Patients in the day hospital treatment group (n = 81, 39.1% 
of the study sample). These patients came to the institutions at 
least 1 morning/afternoon per week (mean 3.5 days/week, SD 1.4, 
median 3.0) and received different forms of psychotherapeutic 
and psychosocial treatment, but slept at home (mean treatment 
duration 10.4 months, SD 4.8, median 12.0). 
 (3) Patients in the inpatient treatment group (n = 80, 38.6% of 
the study sample). These patients stayed at the institutions for
5 days a week and received different forms of psychothera -
 peutic and psychosocial treatment (mean treatment duration 9.1 
months, SD 3.0, median 10.0).
 Day hospital and inpatient programmes typically consisted of 
group psychotherapy as a core element, mostly in combination 
with 1 or more non-verbal or expressive group therapies, indi-
vidual psychotherapy, sociotherapy within the therapeutic com-
munity, coaching for social problems, community meetings and/
or pharmacological treatment. The therapists were all licensed 
psychiatrists or psychologists. On average, they had 14.9 years
(SD = 10.1) of postgraduate clinical experience. The treatments un-
der study can be considered highly representative of regular clinical 
practice in the Netherlands, as therapists did not receive specific 
training for this study and treatment integrity was not monitored. 
The study protocol was approved by the Medical Ethics Commit -
 tee of the Erasmus University Medical Centre in Rotterdam. 
 Assessments
 Baseline Measures. An extensive standard assessment battery 
of instruments was administered to the patients before treatment 
assignment. PD were measured using the Dutch version of the 
Structured Interview for DSM-IV Personality (SIDP-IV)  [47, 48] . 
This interview covers the 11 formal DSM-IV-TR axis II diagnoses 
including PD not otherwise specified, 2 appendix diagnoses (i.e. 
depressive and negativistic PD), and self-defeating PD. Interview-
ers were Master’s level psychologists, who were trained thorough-
ly by one of the authors (R.V.). They received monthly booster 
sessions to avoid deviation from the interviewer guidelines. Inter-
rater reliability was evaluated in 25 videotaped interviews, which 
were rated by 3 observer-raters. Percentage of agreement between 
observer-raters ranged from 84% (avoidant PD) to 100% (schiz-
oid) (median 95%). Intraclass correlation coefficients for the sum 
of DSM-IV PD traits present (i.e. scores ‘2’ or ‘3’) ranged from 0.60 
(schizotypal) through 0.92 (antisocial) (median 0.74).  To measure 
patient characteristics at baseline, the assessment battery also in-
cluded 3 self-report instruments. The first of those was the Dutch 
version of the Dimensional Assessment of Personality Pathology 
Basic Questionnaire (DAPP-BQ), for measuring type and degree 
of personality pathology  [49, 50] . We used patients’ scores on this 
questionnaire on the 4 higher-order factors: emotional dysregula-
tion, dissocial behaviour, inhibition and compulsivity. To mea-
sure the severity of personality pathology we used the 5 higher-
order domains of the Severity Indices of Personality Problems 
(SIPP): self-control, social concordance, identity integration, rela-
tional capacities, and responsibility  [51] . To measure patients’ mo-
tivation for treatment, we used the 2 scales of the Motivation for 
Treatment Questionnaire (MTQ-8): need for help and readiness 
to change  [52] . 
 Outcome Measures. The primary outcome measure was gen-
eral psychiatric symptomatology. This was measured using the 
Dutch version of the Brief Symptom Inventory  [53, 54] , a validat-
ed self-report scale derived from the revised Symptom Check -
 list 90  [55, 56] . In this study, we used the mean score of the 53
items of the Brief Symptom Inventory, i.e. the Global Severity In-
dex (GSI), ranging from 0 to 4. Psychosocial functioning was 
measured with 2 subscales of the Outcome Questionnaire-45 
(OQ-45), interpersonal relations and social role functioning  [57] . 
Health-related quality of life was measured using the EuroQol 
EQ-5D  [58] . All 4 outcome measures, i.e. GSI, OQ-45 interper-
sonal relations, OQ-45 social role, and EQ-5D, were assessed at 
baseline and several follow-up points. Three treatment centres 
conducted follow-up at approximately 12, 24, and 36 months after 
baseline; the other 3 treatment centres conducted follow-up at the 
end of treatment, subsequently after about 6 and 12 months, and 
again at 36 months after baseline. The use of different assessment 
points was due to logistic reasons and was taken into account by 
choosing multilevel modelling as the statistical method for the 
analyses. 
 Statistical Analyses
 We first examined the uncorrected results on all 4 outcome 
measures at 18 months after baseline. We used multilevel model-
ling to deal with the dependency of repeated measures on the 
same subject in time and longitudinal data with observations un-
equally spaced in time (see Outcome Measures). To estimate the 
uncorrected treatment effect at 18 months after baseline we used 
a random intercept and random slope model with time as level I 
and patient number as level II. This resulted in a model with the 
following independent variables: dummy variables indicating 
group membership, time, and interaction between group mem-
bership and time. Subsequently, we calculated within-group ef-
fect sizes (Cohen’s d)  [59] to describe change from baseline to 18 
months per treatment group. 
 However, treatment groups cannot be compared based on the 
uncorrected results in this non-randomised clinical trial as these 
findings might be confounded by initial patient differences. To 
adjust for these differences and to avoid bias in effect estimation, 
we included a ‘multiple propensity score’ in our analyses. The 
classic propensity score is defined as the conditional probability 
of assignment to 1 of 2 treatment groups given a set of observed 
pretreatment variables  [60] . The multiple propensity score is an 
extension of the classic propensity score to more than 2 treatment 
groups  [61] . To identify relevant confounders, we considered a 
long list of social, economic, and diagnostic variables carefully 
selected by both clinicians and researchers, based on the literature 
and clinical knowledge  [62] . All variables significantly related to 
a specific outcome were used to estimate the multiple propensity 
scores in a multinomial regression analysis, with group member-
ship as a dependent variable (see  table 1 for the variables included 
in the GSI propensity score; a complete list of potential/identified 
confounders for all outcome variables is available upon request). 
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A major advantage of the propensity score method, as compared 
to other correction techniques, is the fact that the overlap in pro-
pensity score distributions (and thus the overlap in relevant vari-
ables) between treatment groups can be easily judged and visu-
alised  [63] . From looking at the overlap between the 3 treatment 
groups, it appeared that in spite of some differences, these groups 
were readily comparable. For a detailed description of this meth-
od and its use in psychotherapy research, see Bartak et al.  [62] and 
Spreeuwenberg et al.  [63] . 
 To compare change in outcome variables across treatment 
groups, a more sophisticated multilevel model, now including 
multiple propensity scores, was used. Dependent variables were 
all available change scores observed during follow-up for each of 
the outcome measures. The following independent variables were 
entered in the initial model: dummy variables indicating group 
membership, time, the multiple propensity scores (with their mu-
tual interactions), the 2-way interactions between group member-
ship and time, the 2-way interactions between propensity scores 
and time, the 2-way interactions between propensity scores and 
group membership, and the 3-way interactions between propen-
sity scores, time, and group membership. Then variables were 
eliminated from the model by backward selection to obtain a final 
 Table 1. Variables used for propensity score estimation, outcome GSI
 Variable  Content 
 Age  Patient’s age 
 DAPP-BQ Emotional dysregulation  Unstable affective responding, interpersonal problems 
 DAPP-BQ Dissocial behaviour  Lacking regard for others 
 DAPP-BQ Inhibition  Deriving little enjoyment from intimate relationships 
 DAPP-BQ Compulsivity  Compulsivity and absence of oppositional behaviour 
 MTQ-8 Need for help  Patient’s expressed desire for external help 
 MTQ-8 Readiness to change  Willingness for treatment-seeking behaviour 
 EQ-5D   Quality of life 
 SIPP Self-control  The capacity to tolerate, use and control one’s own emotions 
and impulses 
 SIPP Social concordance  The ability to value someone’s identity, withhold aggressive 
impulses towards others and to work together with others 
 SIPP Identity integration  Coherence of identity; the ability to see oneself and one’s own 
life as stable, integrated and purposive 
 SIPP Relational capacities  The capacity to genuinely care about others as well as
feeling cared for by them, to be able to communicate
personal experiences, and to hear and engage with the
experiences of others often but not necessarily in the context 
of a long-term, intimate relationship 
 SIPP Responsibility  The capacity to set realistic goals and to achieve these goals in 
line with the expectations generated in others 
 GSI  Level of psychiatric symptoms 
 OQ-45 Symptom distress  Level of symptom distress 
 OQ-45 Relational functioning  Level of interpersonal functioning 
 OQ-45 Social role functioning  Level of social and work functioning 
 SIDP-IV Cluster C PD  Number of cluster C PD 
 SIDP-IV Dimensional score cluster C PD  Dimensional score of cluster C PD characteristics 
 Borderline PD  Diagnosis of borderline PD 
 Narcissistic PD  Diagnosis of narcissistic PD 
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best-fit model. This model estimated differences in change scores 
at 18 months after baseline in pairwise comparisons of the 3 treat-
ment groups. 
 Follow-up response was high, enhancing the robustness of the 
multilevel analyses: 12.1% of the respondents completed 1 follow-
up measurement, 6.8% completed 2 follow-up measurements, 
39.6% completed 3 follow-up measurements, 39.1% completed 4 
follow-up measurements, and 2.4% completed 5 follow-up mea-
surements. The analyses were performed using SPSS 17.0 for data 
preparation and Proc Mixed of SAS 9.1.3 for multilevel modelling 
(SAS Institute Inc., Cary, N.C., USA). 
 Results
 Sample Characteristics
 The majority of patients (71%) were female. The mean 
age was 31.3 years (SD 8.5). The level of education was low 
for 33.3%, medium for 19.3%, and high for 47.3%. Fur-
thermore, 78.7% were unmarried, 12.6% were married, 
and 8.7% were divorced or widowed. Most patients 
(77.3%) had a diagnosis of borderline PD, 22.7% had a di-
agnosis of narcissistic PD, 12.6% had a diagnosis of his-
trionic PD, and 8.7% a diagnosis of antisocial PD. There 
was considerable overlap with PD from other clusters: 
40.6% had ‘pure’ cluster B PD (i.e., no comorbid cluster A 
or C PD), 44.9% had a combination of cluster B PD and 
cluster C PD, 3.4% had a combination of cluster B PD and 
cluster A PD, and 11.1% had a combination of cluster B 
PD and both clusters A and C PD. 
 Treatment Compliance
 Before the start of treatment, every patient received an 
allocation to a certain ‘treatment dosage’. According to 
our registration at the end of treatment, about one third 
of all patients (n = 62) underwent exactly the intended 
treatment (31.1% of the outpatient group, 23.8% of the
day hospital group, and 36.7% of the inpatient group). Of 
the 145 patients whose received treatment deviated from 
their intended treatment, 60 (41.4% of the deviating pa-
tients) stayed in treatment shorter than planned (28.1% of 
the deviating patients in the outpatient group, 45.2% in 
the day hospital group, and 45.1% in the inpatient group). 
Of these 60 patients, 40 decided in agreement with their 
therapist that treatment was no longer beneficial or nec-
essary, whereas only 20 patients dropped out of treatment 
prematurely or were forced to leave earlier by the staff. 
From these 20 dropouts, 12 patients were from the day 
hospital group (14.8% of the total day hospital group) and 
8 patients were from the inpatient group (10.0% of the to-
tal inpatient group). All dropouts were treatment drop-
outs (and no study dropouts) who completed follow-up 
measures and were included in the intention-to-treat 
analyses. 
 Treatment Outcome
 Eighteen months after baseline, patients in all 3 set-
tings improved remarkably in terms of psychiatric symp-
toms (GSI), the primary outcome measure ( fig. 2 ;  table 2 ). 
Within-group effect sizes of the uncorrected scores were 
0.55 (medium effect) for outpatient psychotherapy, 0.97 
(large effect) for day hospital psychotherapy, and 1.37 
(very large effect) for inpatient psychotherapy. 
 Improvements were also observed in terms of psycho-
social functioning and quality of life, as can be seen in 
 table  2 . Effect sizes for these outcome measures were 
somewhat smaller compared to psychiatric symptoms, 
with effect sizes varying between 0.64 and 0.87 for social 
role functioning (OQ-45), between 0.30 and 0.89 for in-
terpersonal relations (OQ-45), and between 0.37 and 0.80 
for quality of life (EQ-5D). 
 Improvement between baseline and 18 months proved 
to be significant for patients within all setting groups on 
all 4 outcome measures (p  ! 0.05). 
 Group Comparisons 
 After correction for observed pretreatment differenc-
es by means of the multiple propensity score, the differ-
ences in improvement of psychiatric symptoms between 
outpatient and day hospital treatment and between day 
hospital and inpatient treatment were rather small, with 
  = 0.11 (p = 0.44) and   = 0.18 (p = 0.14), respectively 
0
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 Fig. 2. GSI uncorrected mean scores at baseline and 18-month 
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( table  3 ). However, the difference in improvement be-
tween outpatient and inpatient treatment proved to be 
marginally significant (  = 0.30; p = 0.057) in favour of 
inpatient treatment. 
 Group differences in the improvement of psychosocial 
functioning were smaller than the differences in the im-
provement of psychiatric symptoms ( table 3 ). The same 
holds true for the differences in change scores of quality 
of life, with results that were far from significant. 
 From the inspection of the uncorrected results (i.e., 
without propensity score correction), it appeared that 
propensity score correction reduced the differences be-
tween treatment groups considerably. In other words, 
pretreatment differences played an important role in the 
differential effectiveness observed. 
 Table 2. U ncorrected outcomes (mean  8 SD) and effect sizes in 3 treatment groups for all outcome variables
 Variable  Treatment 
 group 
 Baseline  18
 months 
 Within-group
 effect size,
 Cohen’s d 
 GSI  outpatient (n = 46)  1.52 8 0.78  1.10 8 0.75  0.55 
 day hospital (n = 81)  1.74 8 0.62  1.09 8 0.72  0.97 
 inpatient (n = 80)  1.94 8 0.66  1.02 8 0.69  1.37 
 OQ-45
 Social role 
 outpatient (n = 46)  15.63 8 4.35  12.75 8 4.70  0.64 
 day hospital (n = 81)  16.40 8 4.46  12.89 8 4.68  0.77 
 inpatient (n = 80)  17.33 8 5.33  12.83 8 5.05  0.87 
 OQ-45 
 Interpersonal
 relations 
 outpatient (n = 46)  21.30 8 7.45  19.01 8 7.89  0.30 
 day hospital (n = 81)  21.34 8 5.99  17.65 8 6.41  0.60 
 inpatient (n = 80)  23.59 8 5.94  17.92 8 6.83  0.89 
 EQ-5D  outpatient (n = 46)  0.57 8 0.28  0.67 8 0.26  0.37 
 day hospital (n = 81)  0.47 8 0.27  0.66 8 0.26  0.72 
 inpatient (n = 80)  0.50 8 0.27  0.70 8 0.23  0.80 
 
 
 Table 3. C omparison of change scores from baseline to 18 months after propensity score correction, all outcome 
variables
 Variable  Treatment groups compared  a 95% CI  p value 
 GSI  outpatient (n = 46) vs. day hospital (n = 81) 0.11  –0.17 to 0.40  0.44 
 outpatient (n = 46) vs. inpatient (n = 80) 0.30  –0.01 to 0.60  0.057 
 day hospital (n = 81) vs. inpatient (n = 80) 0.18  –0.06 to 0.42  0.14 
 OQ-45 
 Social role 
 outpatient (n = 46) vs. day hospital (n = 81)  –0.79  –3.13 to 1.54  0.50 
 outpatient (n = 46) vs. inpatient (n = 80)  –0.82  –3.38 to 1.73  0.53 
 day hospital (n = 81) vs. inpatient (n = 80)  –0.03  –1.90 to 1.84  0.98 
 OQ-45
 Interpersonal
 relations 
 outpatient (n = 46) vs. day hospital (n = 81) 0.89  –1.70 to 3.49  0.50 
 outpatient (n = 46) vs. inpatient (n = 80) 2.09  –0.65 to 4.83  0.14 
 day hospital (n = 81) vs. inpatient (n = 80) 1.19  –0.96 to 3.35  0.28 
 EQ-5D  outpatient (n = 46) vs. day hospital (n = 81) 0.02  –0.08 to 0.11  0.71 
 outpatient (n = 46) vs. inpatient (n = 80) 0.07  –0.03 to 0.17  0.16 
 day hospital (n = 81) vs. inpatient (n = 80) 0.05  –0.03 to 0.13  0.18 
 a  Positive coefficients indicate that the last treatment group shown is superior, negative coefficients indicate 
that the first treatment group is superior.  
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 Discussion
 Main Findings
 This is the first study comparing the effectiveness of 
psychotherapy in 3 treatment settings in a large popula-
tion of patients with cluster B PD. Patients in the outpa-
tient, day hospital, and inpatient psychotherapy groups 
showed low dropout rates. They improved in all 3 treat-
ment groups on psychiatric symptoms, psychosocial 
functioning, and quality of life at 18 months after base-
line. Patients in the inpatient psychotherapy group 
showed the strongest improvement, particularly in psy-
chiatric symptoms. This result proved to be marginally 
statistically significant (p = 0.057 for the comparison of 
inpatient and outpatient treatment) even when pretreat-
ment differences of patients were controlled for with the 
multiple propensity score. 
 Strengths and Limitations
 A clear strength of the present study is its external va-
lidity and clinical utility since it was conducted in regular 
clinical practice, not under experimental conditions  [64] . 
Remarkably, dropout rates were low compared to other 
studies conducted in PD populations  [65] . A second 
strength is the powerful statistical control of potential 
confounders, using the multiple propensity score meth-
odology. Finally, a major asset of this study is its large 
sample size. All this enabled the comparison of outpa-
tient, day hospital, and inpatient psychotherapeutic treat-
ment while keeping sufficient statistical power. 
 Despite these strengths, the study had several limita-
tions. First, even though we controlled for all observed 
pretreatment differences, it cannot be ruled out that
results were influenced by unobserved confounders. To
minimise this risk as much as possible, a broad range of 
possible confounders was carefully selected and mea-
sured, based on both clinical and empirical knowledge 
 [62] , including variables identified in the literature as sig-
nificant predictors of therapy outcome or process, such 
as severity of baseline psychopathology, previous hospi-
talisation, and substance misuse  [66–71] . Only variables 
significantly related to treatment outcome were included 
in the propensity score. In the present sample (and con-
trary to previous research), this appeared not to be the 
case for previous hospitalisation and substance misuse. 
However, even when considerably reducing the possibil-
ity of important confounders being overlooked, not all 
possible variables could be covered in interviews and 
questionnaires at baseline and therefore several variables, 
such as self-harm  [72] , were not measured. Second, for 
ethical reasons, a control group receiving no treatment at 
all was not included. This omission is mitigated by the 
fact that several previous studies have convincingly 
shown that specialised psychotherapeutic treatment pro-
vides better outcomes than various control conditions 
(for example waiting list controls)  [20, 24] . Third, even 
though the study sample covers the whole range of cluster 
B PD (borderline PD, narcissistic PD, histrionic PD, and 
antisocial PD), the majority of patients had a diagnosis of 
borderline PD. This makes the conclusions most appli-
cable to this borderline group and only to a lesser extent 
to the other 3 diagnostic groups. Fourth, the cut-off point 
between outpatient and day hospital treatment was arbi-
trary. We defined outpatient treatment as a low-intensive 
treatment with a maximum of 2 sessions of therapy per 
week. As soon as more therapy elements were added, we 
called it ‘day hospital’ treatment. This implies that our 
group of day hospital treatments was a heterogeneous 
one, varying from 1 morning/afternoon per week to 5 
days per week. Therefore, conclusions about the effective-
ness of specific day hospital treatments have to be drawn 
carefully, bearing this cut-off score in mind. 
 Research Implications
 What are the implications of the present results for fu-
ture research? 
 First, inpatient treatment has been largely margin-
alised in the literature. Only a handful of studies have 
investigated its usefulness, most of them with promising 
results  [36, 73–76] . Moreover, in the last 2 decades, inpa-
tient treatment for PD has become infrequent in clinical 
practice  [38] . In recent practice guidelines (NICE)  [77,
78] – based on scientific knowledge – inpatient treatment 
is only recommended as a short-term crisis intervention. 
In a report of the NIMH on treatment of PD, it is also ex-
plicitly stated that there are ‘no plans to extend this level 
of residential provision’  [79] . In the light of the present 
results, however, specialised inpatient treatment deserves 
to be considered as a valuable treatment option for pa-
tients with cluster B PD and future research should not a 
priori exclude this treatment setting from effectiveness 
studies. In a recent study on cluster C PD, short inpatient 
treatment also emerged as the treatment with the best re-
sults, compared to other treatment modalities  [80] . On 
the other hand, Chiesa et al.  [38] showed in a naturalistic 
study that specialised low-intensive treatment can equal 
(or even surpass) the results of traditional inpatient treat-
ment. And indeed, in our study, we did not find a signif-
icant difference between day hospital and inpatient treat-
ment. Therefore, future research should focus more on 
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the question of ‘ideal dosage’ of treatment for patients 
with PD. As our study covers the whole range of cluster B 
PD and therefore a heterogeneous group of patients in 
many aspects, results might be different across specific 
subgroups of patients  [81, 82] . For instance, very vulner-
able patients may not be able to tolerate the therapeutic 
‘pressure’ that is often characteristic of full-time inpatient 
treatment or the subculture of patients’ living together 
 [65] . This patient group might benefit much more from a 
long-term structured day hospital programme, for exam-
ple mentalization-based treatment  [17] . It is recommend-
ed to further investigate these potential matching factors. 
This will enable clinicians to make specific treatment rec-
ommendations for different subgroups of cluster B PD 
patients and to develop more sophisticated clinical prac-
tice guidelines. 
 Second, when randomised designs are impossible or 
unfeasible, important research questions have to be an-
swered by means of non-randomised clinical trials. In 
these cases, researchers have to control for as many pa-
tient variables as possible in a statistically sound way. 
This is essential in order not to draw premature and pos-
sibly misleading conclusions. 
 Public Health Significance
 The marginally significant corrected results make it 
difficult to definitely determine the best treatment set-
ting for patients with cluster B PD. After propensity score 
correction, the favourable effect of inpatient psychother-
apy on psychiatric symptoms is of marginal statistical 
significance, but still clinically worthwhile. This effect 
cannot be explained by the influence of dropout rates, as 
treatment compliance was even lower in the inpatient 
group (10.0% dropout rate) compared to the outpatient 
group (0.0% dropout rate). However, the marginal statis-
tical significance does not allow us to draw definite con-
clusions. Possibly, this may be caused by a lack of power, 
which could be solved by an even larger sample size. The 
effect might also become larger when the observation pe-
riod is increased. A question for future research is there-
fore whether a certain treatment setting is superior over 
a longer-term perspective. It could be speculated that the 
outcome areas psychosocial functioning and quality of 
life have a slower pace of change compared to psychiatric 
symptoms and might also show a differential effective-
ness of treatments at a later stage. Yet this remains con-
jecture and future research is needed urgently to shed 
more light on this question. Another future area of explo-
ration should be cost-effectiveness. Expensive treatments 
can earn back the investment made and may even lead to 
cost savings in the long run, because patients probably 
consume less additional forms of care after leaving an in-
tensive (and effective) treatment. However, in the absence 
of long-term cost-effectiveness data, an answer to this 
question cannot be provided here. 
 In conclusion, this study indicates that patients with 
cluster B PD improve in outpatient, day hospital, and in-
patient psychotherapeutic treatment. In addition, we ob-
served a small trend towards larger improvements of psy-
chiatric symptoms in the inpatient setting compared to 
the outpatient setting. Future studies are needed to fur-
ther investigate the effect of different treatment dosages 
and possible differences in treatment effectiveness for 
different subgroups of patients. Meanwhile, inpatient 
therapy should still be considered a valuable option for 
patients with cluster B PD and should receive as much at-
tention as other treatment options, both in research and 
clinical practice. 
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